OxyPrem completes swarm financing

(CONNECT) OxyPrem has officially closed its crowdfunding campaign on Capital Cell, according to a statement from the manufacturer of oxygen sensors for the brains of premature babies. According to the campaign page, 2,911,803 euros of the targeted 2.3 million were raised in the crowdfunding round, which runs until February 28. The valuation of OxyPrem is 17.1 million euros.

OxyPrem, based in Schlieren and Zurich, develops optical sensors that precisely monitor the oxygen content in the brain non-invasively and continuously. This helps medical teams to react in time and counteract insufficient oxygen levels to prevent irreversible brain damage and lifelong disabilities. According to OxyPrem, around 10 percent of all people are born prematurely. These infants are at high risk of lifelong brain damage caused by harmful oxygen levels in the brain.

Commenting on the investment in OxyPrem, Capital Cell says that the technology on which the sensors are based has shown that it can reduce false positives and negatives from one in six measurements to just one in 200. reduced. It is based on 13 clinical studies and 17 publications, among other things. The first product, launched as OxyPrem 1.4, has already been used for over 300 extremely premature babies in 38 neonatal intensive care units in Europe and India. ce/gba